In an attempt to prevent the misuse of Wegovy, an analogue of GLP-1 indicated in the treatment of obesity recently marketed in France, its initial prescription is reserved for specialists in endocrinology-diabetology-nutrition or holders of specialized transversal training “Nutrition applied”. But these restrictions do not prevent the French Society of Endocrinology (SFE) from sounding the alarm.
No self-medication
“While this treatment provides an effective treatment option for patients with severe obesity, it is by no means a one-size-fits-all solution. Self-medication or use of Wegovy outside of endocrinological monitoring presents significant risks, including serious adverse effects and long-term consequences. explains its president, Professor Gérald Raverot, in a press release dated today.
In addition to gastrointestinal disturbances, headaches and fatigue, the use of Wegovy without medical supervision may cause “nutritional deficiencies, malnutrition and/or worsening of eating disorders”adds Dr Helena Mosbah, endocrinologist in Paris.
The SFE therefore reminds that Wegovy must “under no circumstances” be used for aesthetic purposes. The body calls on patients and prescribers “to exercise caution and responsibility” to guarantee safe use of the drug. And so that resales on social networks stop.
Health
Related News :